VivoSim Labs, Inc. Common Stock (VIVS) Stock Price

VIVSStock

$0.29−84.74%52W

Market Cap$3.82M

P/E—

PEG Ratio—

Div yield—

Beta1.50

VIVS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-97.22%

Price vs S&P 500 (4W)-16.28%

VGM Score15.57

Book Value / Share (Quarterly)$1.70

P/TBV (Annual)0.36x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-29.26%

Cash Flow / Share (Quarterly)$-3.74

Price vs S&P 500 (YTD)-97.06%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-10567.18%

EPS (TTM)$-5.33

10-Day Avg Trading Volume0.89M

EPS Excl Extra (TTM)$-5.33

Revenue Growth (5Y)-42.03%

EPS (Annual)$-5.35

ROI (Annual)-23.71%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-6236.56%

Cash / Share (Quarterly)$1.74

Revenue Growth QoQ (YoY)-21.57%

ROA (Last FY)-187.42%

Revenue Growth TTM (YoY)-9.03%

EBITD / Share (TTM)$-4.36

ROE (5Y Avg)-124.91%

Operating Margin (TTM)-8768.70%

Cash Flow / Share (Annual)$-3.74

P/B Ratio0.79x

P/B Ratio (Quarterly)1.06x

Net Income / Employee (Annual)$-1,064,800

EV / Revenue (TTM)-11.61x

Net Interest Coverage (TTM)-4.05x

ROA (TTM)-153.77%

EPS Incl Extra (Annual)$-5.35

Current Ratio (Annual)2.38x

Quick Ratio (Quarterly)2.18x

3-Month Avg Trading Volume3.95M

52-Week Price Return-84.74%

Revenue / Employee (TTM)$10,100

P/S Ratio (Annual)26.75x

Asset Turnover (Annual)0.02x

52-Week High$5.30

Operating Margin (5Y Avg)-7385.48%

EPS Excl Extra (Annual)$-5.35

26-Week Price Return-85.29%

Quick Ratio (Annual)2.18x

13-Week Price Return-78.22%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.38x

Enterprise Value$-1.52M

Revenue / Share Growth (5Y)-21.94%

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$10,100

Inventory Turnover (Annual)0.03x

Pretax Margin (Annual)-10565.65%

Cash / Share (Annual)$1.74

3-Month Return Std Dev136.96%

Gross Margin (5Y Avg)88.72%

Net Income / Employee (TTM)$-1,064,800

ROE (Last FY)-23.71%

Net Interest Coverage (Annual)-257.00x

EPS Basic Excl Extra (Annual)$-5.35

Receivables Turnover (TTM)4.23x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.33

Receivables Turnover (Annual)4.23x

ROI (TTM)-15.56%

P/S Ratio (TTM)26.75x

Pretax Margin (5Y Avg)-6235.61%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$5.53

Price vs S&P 500 (52W)-103.30%

Year-to-Date Return-84.24%

5-Day Price Return-2.29%

EPS Normalized (Annual)$-5.35

ROA (5Y Avg)-110.97%

Net Profit Margin (Annual)-10567.18%

Month-to-Date Return-17.21%

EBITD / Share (Annual)$-4.35

Operating Margin (Annual)-8768.70%

ROI (5Y Avg)-124.91%

EPS Basic Excl Extra (TTM)$-5.33

P/B Ratio (Annual)0.36x

Inventory Turnover (TTM)0.03x

Pretax Margin (TTM)-10565.65%

Book Value / Share (Annual)$5.53

Price vs S&P 500 (13W)-80.18%

Beta1.50x

Revenue / Share (TTM)$0.05

ROE (TTM)-15.56%

52-Week Low$0.26

gGradeF

mGradeF

vgmGradeF

VIVS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2024	Feb 19, 2025	-$2.40	-$2.28	+5.00%(+$0.12)
Q3 2024	Nov 8, 2024	-$2.64	-$1.68	+36.36%(+$0.96)
Q2 2024	Aug 5, 2024	-$3.96	-$2.76	+30.30%(+$1.20)
Q1 2024	May 10, 2024	-$5.04	-$8.04	-59.52%(-$3.00)

VIVS Analyst Recommendations

Sep 2021

Oct 2021

Nov 2021

Dec 2021

2.29

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
VIVSVivoSim Labs, Inc. Common Stock	—	F	F	$0.29
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About VivoSim Labs, Inc. Common Stock

VivoSim Labs Inc (formerly Organovo Holdings Inc) is a biotechnology company developing FXR314 for inflammatory bowel disease, validated through its proprietary 3D human tissue modeling platform. The company also generates revenue through liver toxicology screening services and drug safety profiling offerings for pharmaceutical and biotech clients across all stages of drug development.